Universidade Federal do Rio de Janeiro
ufrj.brLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
123
Active
7
Phase 3
11
Total enrollment
15,566
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Rectus Sheath Block | — | — | — | — | — | 1 | |
| Rectus Sheath Block with Clonidine | — | — | — | — | — | 1 |
Next readouts
- 2025-12-16
Top conditions
- Healthy9
- Obesity8
- Aging8
- Panic Disorder5
- Insulin Resistance4
- Hypertension3
- Dyslipidemia3
- Intensive Care Unit Acquired Weakness3
Frequently asked questions about Universidade Federal do Rio de Janeiro
- How many clinical trials does Universidade Federal do Rio de Janeiro have on ClinicalTrials.gov?
- Universidade Federal do Rio de Janeiro is listed as the lead sponsor on 123 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Universidade Federal do Rio de Janeiro's trials are in Phase 3?
- 11 of Universidade Federal do Rio de Janeiro's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Universidade Federal do Rio de Janeiro focus on?
- Universidade Federal do Rio de Janeiro's most-studied conditions on ClinicalTrials.gov are Healthy, Obesity, Aging, Panic Disorder, Insulin Resistance.
- When are Universidade Federal do Rio de Janeiro's next clinical trial readouts?
- Universidade Federal do Rio de Janeiro has 1 upcoming primary-completion readout tracked here; the soonest is “Clonidine in Ultrasound-guided Rectus Sheath Block for Outpatient Umbilical Hernioplasty”, expected around 2025-12-16.